Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Please provide your email address to receive an email when new articles are posted on . “We found a stepwise greater loss of lung density with increasing exacerbation frequency, predominantly in ...

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing ...

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

Certain neighborhood characteristics, including higher poverty, more uninsured residents, and lower educational attainment, ...

In an observational study that began enrollment last month, researchers will determine if continuous, remote lung sound ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...